| Combination antiretroviral therapy and the risk of myocardial infarction Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group New England Journal of Medicine 349 (21), 1993-2003, 2003 | 2106 | 2003 |
| Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy AJ Rodger, V Cambiano, T Bruun, P Vernazza, S Collins, J Van Lunzen, ... Jama 316 (2), 171-181, 2016 | 1691 | 2016 |
| Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: a multi-cohort collaboration D: A: D Study Group The Lancet 371 (9622), 1417-1426, 2008 | 1162 | 2008 |
| Sociodemographic and psychological variables influencing adherence to antiretroviral therapy V Gordillo, J del Amo, V Soriano, J González-Lahoz Aids 13 (13), 1763-1769, 1999 | 995 | 1999 |
| Raltegravir with optimized background therapy for resistant HIV-1 infection RT Steigbigel, DA Cooper, PN Kumar, JE Eron, M Schechter, M Markowitz, ... New England Journal of Medicine 359 (4), 339-354, 2008 | 906 | 2008 |
| Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection DA Cooper, RT Steigbigel, JM Gatell, JK Rockstroh, C Katlama, P Yeni, ... New England Journal of Medicine 359 (4), 355-365, 2008 | 604 | 2008 |
| Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management AMJ Wensing, DA Van De Vijver, G Angarano, B Åsjö, C Balotta, E Boeri, ... The Journal of infectious diseases 192 (6), 958-966, 2005 | 557 | 2005 |
| Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs FL Altice, A Kamarulzaman, VV Soriano, M Schechter, GH Friedland The Lancet 376 (9738), 367-387, 2010 | 554 | 2010 |
| Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy JK Rockstroh, A Mocroft, V Soriano, C Tural, MH Losso, A Horban, O Kirk, ... The Journal of infectious diseases 192 (6), 992-1002, 2005 | 549 | 2005 |
| Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV–HIV International Panel V Soriano, M Puoti, M Sulkowski, A Cargnel, Y Benhamou, M Peters, ... Aids 21 (9), 1073-1089, 2007 | 463 | 2007 |
| Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study N Friis-Møller, R Thiebaut, P Reiss, R Weber, A D'Arminio Monforte, ... European journal of cardiovascular prevention & rehabilitation 17 (5), 491-501, 2010 | 438 | 2010 |
| Update of the statements on biology and clinical impact of occult hepatitis B virus infection G Raimondo, S Locarnini, T Pollicino, M Levrero, F Zoulim, AS Lok, ... Journal of hepatology 71 (2), 397-408, 2019 | 410 | 2019 |
| Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir J Sheldon, N Camino, B Rodés, A Bartholomeusz, M Kuiper, F Tacke, ... Antiviral therapy 10 (6), 727-734, 2005 | 407 | 2005 |
| Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV–HCV International Panel V Soriano, M Sulkowski, C Bergin, A Hatzakis, P Cacoub, C Katlama, ... Aids 16 (6), 813-828, 2002 | 394 | 2002 |
| Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration R Kantor, DA Katzenstein, B Efron, AP Carvalho, B Wynhoven, P Cane, ... PLoS medicine 2 (4), e112, 2005 | 391 | 2005 |
| Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes B Ledergerber The Lancet 364 (9428), 51-62, 2004 | 391 | 2004 |
| Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy M Núñez, R Lana, JL Mendoza, L Martín-Carbonero, V Soriano JAIDS Journal of Acquired Immune Deficiency Syndromes 27 (5), 426-431, 2001 | 368 | 2001 |
| Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study JJ Eron, B Clotet, J Durant, C Katlama, P Kumar, A Lazzarin, ... The Journal of infectious diseases 207 (5), 740-748, 2013 | 367 | 2013 |
| The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference A Hatzakis, S Wait, J Bruix, M Buti, M Carballo, M Cavaleri, M Colombo, ... Journal of viral hepatitis 18, 1-16, 2011 | 352 | 2011 |
| Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome M Puoti, R Bruno, V Soriano, F Donato, GB Gaeta, GP QUINZAN, ... AIDS 18, 2285-93, 2004 | 345* | 2004 |
Pablo BarreiroHospital La Paz. UNIR. Universidad EuropeaVerified email at unir.net
